Bendamustine–rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

Lymphoid Neoplasia, Rituximab Versus Chop, Oncology +10

European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision

Peter Van den Bergh, Robert D. M. Hadden, P. Bouché et al. · European Journal of Neurology · 2010 · 1.1K citations

Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathy

Marinos C. Dalakas, Goran Rakočević, Mohammad Salajegheh et al. · Annals of Neurology · 2009 · 305 citations

Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies

Ingemar S.J. Merkies · Journal of Neurology Neurosurgery & Psychiatry · 2002 · 299 citations · Full text

How I treat Waldenström macroglobulinemia

Steven P. Treon · Blood · 2015 · 285 citations · Full text